Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Faster-acting Insulin Aspart in Children and Adolescents with Type 1 Diabetes
NCT02670915Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- May 2016
- Primary completion
- Feb 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 18
01
Overview
A Phase 3 trial of insulin aspart in type 1 diabetes mellitus (T1D), sponsored by Novo Nordisk. Started May 2016; status: completed.
02
Drugs
insulin aspart
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02670915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02670915.